GGrantIndex
← Leaderboards

David A Wohl

Univ Of North Carolina Chapel Hill

Google Scholar ↗PubMed ↗ORCID ↗
$27,961,733
Attributed
$56,453,526
Total exposure
55
Grants
39
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.7M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$56,453,526 · 55

By mechanism

UM1$24,477,809 · 1
R01$22,938,671 · 8
M01$7,747,415 · 44
K24$911,397 · 1
R21$378,234 · 1

Top collaborators

Most similar at Univ Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHiv InfectionsHuman SubjectHuman Therapy EvaluationResearch PersonnelCaringAids TherapyEnrollmentPharmaceutical PreparationsVirusUnited States National Institutes Of HealthViralPersonsSamplingEpidemicCohortAreaClinical TrialsAntiretroviral TherapyInvestigationRecruitParticipantBaseAids Prevention

Grant awards (148)

University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$4,889,495
UM1 · FY2025 · AI
The Protective and Pathologic Features of the EVD Survivor Immune System$697,315
R01 · FY2025 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$3,992,131
UM1 · FY2024 · AI
The Protective and Pathologic Features of the EVD Survivor Immune System$691,767
R01 · FY2024 · AI
HIV PrEP Perspectives of Liberian Adolescent Girls and Young Women and their Providers$139,701
R21 · FY2024 · MH · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 Supplement$69,163
UM1 · FY2024 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$4,091,472
UM1 · FY2023 · AI
The Protective and Pathologic Features of the EVD Survivor Immune System$715,921
R01 · FY2023 · AI
Patient and Provider perspectives on long acting injectable ART$501,620
R01 · FY2023 · MH · contact PI
HIV PrEP Perspectives of Liberian Adolescent Girls and Young Women and their Providers$238,533
R21 · FY2023 · MH · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$4,360,341
UM1 · FY2022 · AI
Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa$725,157
R01 · FY2022 · AI · contact PI
Patient and Provider perspectives on long acting injectable ART$550,178
R01 · FY2022 · MH · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$356,641
UM1 · FY2022 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$5,609,272
UM1 · FY2021 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$1,109,294
UM1 · FY2021 · AI
Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa$727,837
R01 · FY2021 · AI · contact PI
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus Disease$642,920
R01 · FY2021 · AI · contact PI
Patient and Provider perspectives on long acting injectable ART$611,865
R01 · FY2021 · MH · contact PI
Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa$724,693
R01 · FY2020 · AI · contact PI
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus Disease$647,747
R01 · FY2020 · AI · contact PI
Patient and Provider perspectives on long acting injectable ART$636,663
R01 · FY2020 · MH · contact PI
Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa$729,986
R01 · FY2019 · AI · contact PI
Patient and Provider perspectives on long acting injectable ART$672,352
R01 · FY2019 · MH · contact PI
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus Disease$648,834
R01 · FY2019 · AI · contact PI
Prevalence, Pathogenesis, and Persistence of Lassa Fever in West Africa$751,045
R01 · FY2018 · AI · contact PI
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus Disease$655,110
R01 · FY2018 · AI · contact PI
Mentoring New Investigators in Criminal Justice HIV Prevention and Treatment$181,621
K24 · FY2018 · DA · contact PI
Clinical Sequelae and Urogenital Viral Dynamics in Survivors of Ebola Virus Disease$665,447
R01 · FY2017 · AI · contact PI
Mentoring New Investigators in Criminal Justice HIV Prevention and Treatment$182,403
K24 · FY2017 · DA · contact PI
Mentoring New Investigators in Criminal Justice HIV Prevention and Treatment$182,441
K24 · FY2016 · DA · contact PI
Mentoring New Investigators in Criminal Justice HIV Prevention and Treatment$182,116
K24 · FY2015 · DA · contact PI
RCT of an augmented test, treat, link, & retain model for NC and Texas prisoners$150,480
R01 · FY2015 · DA · contact PI
RCT of an augmented test, treat, link, & retain model for NC and Texas prisoners$641,873
R01 · FY2014 · DA · contact PI
Mentoring New Investigators in Criminal Justice HIV Prevention and Treatment$182,816
K24 · FY2014 · DA · contact PI
RCT of an augmented test, treat, link, & retain model for NC and Texas prisoners$940,095
R01 · FY2013 · DA · contact PI
RCT of an augmented test, treat, link, & retain model for NC and Texas prisoners$1,483,004
R01 · FY2012 · DA · contact PI
Separation of HIV Infected Prison Inmates: Perceptions and Clinical Outcomes$2,535
R01 · FY2012 · HD · contact PI
RCT of an augmented test, treat, link, & retain model for NC and Texas prisoners$2,031,974
R01 · FY2011 · DA · contact PI
RCT of an augmented test, treat, link, & retain model for NC and Texas prisoners$62,772
R01 · FY2011 · DA · contact PI
RCT of an augmented test, treat, link, & retain model for NC and Texas prisoners$1,540,949
R01 · FY2010 · DA · contact PI
Incarceration and HIV-Infected Inmates$299,846
R01 · FY2010 · MH · contact PI
Incarceration and HIV-Infected Inmates$635,810
R01 · FY2009 · MH · contact PI
Incarceration and HIV-Infected Inmates$600,323
R01 · FY2008 · MH · contact PI
CLINICAL TRIAL: PHASE I/II URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY (ACTG A522$15,781
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ENFURVITIDE (T-20) INTENSIFICATION FOR LOW LEVEL VIREMIA (THE LO$14,566
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: MRK AD5 HIV-1 GAG VACCINE IN HIV-1 SUBJECTS WHO INTERUPT THERAPY$13,352
M01 · FY2008 · RR · contact PI
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION$8,498
M01 · FY2008 · RR · contact PI
LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS (SLAM-C)$7,283
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A5235 - MINOCYCLINE IN THE TREATMENT OF HIV-ASSOCIATED COGNITIVE$3,035
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: TWO DOSES OF GW433908/RITONAVIR GIVEN WITH ABACAVIR/LAMIVUDINE C$1,530
M01 · FY2008 · RR · contact PI
Incarceration and HIV-Infected Inmates$471,421
R01 · FY2007 · MH · contact PI
HIV+ Prison Releases to Access to HIV Care and Services$242,471
R01 · FY2007 · DA · contact PI
MRK AD5 HIV-1 GAG VACCINE IN HIV-1 SUBJECTS WHO INTERUPT THERAPY$108,658
M01 · FY2007 · RR · contact PI
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION$100,649
M01 · FY2007 · RR · contact PI
NUTRICEUTICALS D-GLUCARATE, SILYMARIN AND PIPERINE ON PHARMACOKINETICS$91,502
M01 · FY2007 · RR · contact PI
TWO DOSES OF GW433908/RITONAVIR GIVEN WITH ABACAVIR/LAMIVUDINE COMBO$49,180
M01 · FY2007 · RR · contact PI
EZETIMIBE THERAPY FOR DYSLIPIDEMIA IN PATIENTS RECEIVING HIV THERAPY$46,895
M01 · FY2007 · RR · contact PI
LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS (SLAM-C)$28,593
M01 · FY2007 · RR · contact PI
PHASE 3 COMPARISON OF LOPINAVIR/RITONAVIR EFAVIRENZ STAVUDINE LAMIVUDINE FOR INI$27,450
M01 · FY2007 · RR · contact PI
POTENT COMBINATION OF ANTIRETROVIRAL REGIMEN IN AFRICAN-AMERICAN MEN AND WOMEN$18,299
M01 · FY2007 · RR · contact PI
ENFURVITIDE (T-20) INTENSIFICATION FOR LOW LEVEL VIREMIA (THE LOLA STUDY)$3,431
M01 · FY2007 · RR · contact PI
PHASE II ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS WITH DECREASED BONE D$1,143
M01 · FY2007 · RR · contact PI
PHASE I/II URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY (ACTG A5229)$1,143
M01 · FY2007 · RR · contact PI
NUTRICEUTICALS D-GLUCARATE, SILYMARIN AND PIPERINE ON PHARMACOKINETICS$526,471
M01 · FY2006 · RR · contact PI
HIV+ Prison Releases to Access to HIV Care and Services$246,541
R01 · FY2006 · DA · contact PI
EZETIMIBE THERAPY FOR DYSLIPIDEMIA IN PATIENTS RECEIVING HIV THERAPY$176,156
M01 · FY2006 · RR · contact PI
POTENT COMBINATION OF ANTIRETROVIRAL REGIMEN IN AFRICAN-AMERICAN MEN AND WOMEN$160,052
M01 · FY2006 · RR · contact PI
ACTG A5142$136,898
M01 · FY2006 · RR · contact PI
MRK AD5 HIV-1 GAG VACCINE IN HIV-1 SUBJECTS WHO INTERUPT THERAPY$72,476
M01 · FY2006 · RR · contact PI
VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CMV VIREMIA (ACTG A5030)$66,436
M01 · FY2006 · RR · contact PI
TWO DOSES OF GW433908/RITONAVIR GIVEN WITH ABACAVIR/LAMIVUDINE COMBO$58,383
M01 · FY2006 · RR · contact PI
LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS (SLAM-C)$34,224
M01 · FY2006 · RR · contact PI
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION$32,213
M01 · FY2006 · RR · contact PI
PHASE II ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS WITH DECREASED BONE D$22,144
M01 · FY2006 · RR · contact PI
COMBINATION THERAPY WITH FISH OIL SUPPLEMENT AND FENOFIBRATE$6,040
M01 · FY2006 · RR · contact PI
ANTIRETROVIRAL SWITCH AT LOWER VS HIGHER HIV-1 RNA LEVELS WITH RELAPSE$2,014
M01 · FY2006 · RR · contact PI
HIV+ Prison Releases to Access to HIV Care and Services$537,364
R01 · FY2005 · DA
ACTG A5142$178,053
M01 · FY2005 · RR
POTENT COMBO ANTIRETROVIRAL REGIMEN IN AA MEN AND WOMEN$170,600
M01 · FY2005 · RR
VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CMV VIREMIA (ACTG A5030)$101,862
M01 · FY2005 · RR
PHASE II ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS WITH DECREASED BONE D$43,063
M01 · FY2005 · RR
IMMUNE RESPONSE TO PNEUMOCOCCAL VACCINE IN PATIENTS WITH HIV$7,453
M01 · FY2005 · RR
ANTIRETROVIRAL SWITCH AT LOWER VS HIGHER HIV-1 RNA LEVELS WITH RELAPSE$5,796
M01 · FY2005 · RR
COMBINATION THERAPY WITH FISH OIL SUPPLEMENT AND FENOFIBRATE$4,142
M01 · FY2005 · RR
NUTRICEUTICALS D-GLUCARATE, SILYMARIN AND PIPERINE ON PHARMACOKINETICS$2,484
M01 · FY2005 · RR
FISH OIL SUPPLEMENTATION PLUS DIET AND EXCERCISE VS DIET AND EXERCISE ALONE-HIV$827
M01 · FY2005 · RR
METFORMIN AND ROSIGLITAZONE ALONE OR IN COMBINATION IN HIV-INFECTED SUBJECTS$827
M01 · FY2005 · RR
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION$827
M01 · FY2005 · RR
HIV+ Prison Releases to Access to HIV Care and Services$523,811
R01 · FY2004 · DA
ACTG A5142$157,646
M01 · FY2004 · RR
Valganciclovir Pre-Emptive Therapy for CMV Viremia (ACTG A5030)$90,310
M01 · FY2004 · RR
FISH OIL SUPPLEMENTATION PLUS DIET AND EXCERCISE VS. DIET AND EXERCISE ALONE-HIV$83,180
M01 · FY2004 · RR
IMMUNE RESPONSE TO PNEUMOCOCCAL VACCINE IN PATIENTS WITH HIV$39,610
M01 · FY2004 · RR
PHASE II ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS WITH DECREASED BONE D$32,481
M01 · FY2004 · RR
POTENT COMBINATION OF ANTIRETROVIRAL REGIMEN IN AFRICAN-AMERICAN MEN AND WOMEN$19,804
M01 · FY2004 · RR
METFORMIN AND ROSIGLITAZONE ALONE OR IN COMBINATION IN HIV-INFECTED SUBJECTS$15,845
M01 · FY2004 · RR
COMBINATIONS OF POTENT ANTIRETROVIRAL THERAPY, HIV-SPECIFIC IMMUNIZATIONS$11,883
M01 · FY2004 · RR
Antiretroviral Switch at Lower vs. Higher HIV-1 RNA Levels with Relapse$5,545
M01 · FY2004 · RR
HIV+ Prison Releases to Access to HIV Care and Services$530,945
R01 · FY2003 · DA
HIV AND CMV VIRAL BURDEN AND DEVELOPMENT OF CMV END-ORGAN DISEASE$190,747
M01 · FY2002 · RR
ACTG 379 DISCONTINUING MAINTENANCE THERAPY FOR CMV RETINITIS$190,747
M01 · FY2002 · RR
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)$190,747
M01 · FY2002 · RR
GANCICLOVIR CIDOFOVIR CMV RETINITIS TRIAL$190,747
M01 · FY2002 · RR
THALIDOMIDE FOR TREATMENT OF RECURRENT APHTHOUS ULCERS IN HIV$190,747
M01 · FY2002 · RR
A LONGITUDINAL STUDY OF THE PREDICTIVE VALUE OF QUANTITATIVE CMV$190,747
M01 · FY2002 · RR
GANCICLOVIR CIDOFOVIR CMV RETINITIS TRIAL$294,555
M01 · FY2001 · RR
ACTG 379 DISCONTINUING MAINTENANCE THERAPY FOR CMV RETINITIS$294,555
M01 · FY2001 · RR
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)$294,555
M01 · FY2001 · RR
THALIDOMIDE FOR TREATMENT OF RECURRENT APHTHOUS ULCERS IN HIV$294,555
M01 · FY2001 · RR
HIV AND CMV VIRAL BURDEN AND DEVELOPMENT OF CMV END-ORGAN DISEASE$294,555
M01 · FY2001 · RR
A LONGITUDINAL STUDY OF THE PREDICTIVE VALUE OF QUANTITATIVE CMV$294,555
M01 · FY2001 · RR
A LONGITUDINAL STUDY OF THE PREDICTIVE VALUE OF QUANTITATIVE CMV$190,747
M01 · FY2001 · RR
HIV AND CMV VIRAL BURDEN AND DEVELOPMENT OF CMV END-ORGAN DISEASE$190,747
M01 · FY2001 · RR
ACTG 379 DISCONTINUING MAINTENANCE THERAPY FOR CMV RETINITIS$190,747
M01 · FY2001 · RR
GANCICLOVIR CIDOFOVIR CMV RETINITIS TRIAL$190,747
M01 · FY2001 · RR
THALIDOMIDE FOR TREATMENT OF RECURRENT APHTHOUS ULCERS IN HIV$190,747
M01 · FY2001 · RR
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)$190,747
M01 · FY2001 · RR
GANCICLOVIR CIDOFOVIR CMV RETINITIS TRIAL$294,555
M01 · FY2000 · RR
GANCICLOVIR CIDOFOVIR CMV RETINITIS TRIAL$294,555
M01 · FY2000 · RR
GANCICLOVIR CIDOFOVIR CMV RETINITIS TRIAL$294,555
M01 · FY2000 · RR
ACTG 379 DISCONTINUING MAINTENANCE THERAPY FOR CMV RETINITIS$241
M01 · FY2000 · RR
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)$241
M01 · FY2000 · RR
GANCICLOVIR CIDOFOVIR CMV RETINITIS TRIAL$241
M01 · FY2000 · RR
THE LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR
ACTG 379 DISCONTINUING MAINTENANCE THERAPY FOR CMV RETINITIS$0
M01 · FY2000 · RR
A LONGITUDINAL STUDY OF QUANTITATIVE CMV IN PYS W/ AIDS$0
M01 · FY2000 · RR
ACTG 379 DISCONTINUING MAINTENANCE THERAPY FOR CMV RETINITIS$0
M01 · FY2000 · RR
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)$0
M01 · FY2000 · RR
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)$0
M01 · FY2000 · RR
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)$0
M01 · FY2000 · RR
THALIDOMIDE FOR RECURRENT APHTHOUS STOMATITIS IN HIV$0
M01 · FY2000 · RR
ABT378/RITONAVIR W/ REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2000 · RR
ABT378/RITONAVIR W/ REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2000 · RR
ABT378/RITONAVIR W/ REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2000 · RR
HIV &CMV &DEVELOPMENT OF CMV END-ORGAN DISEASE$0
M01 · FY2000 · RR
ACTG 379 DISCONTINUING MAINTENANCE THERAPY FOR CMV RETINITIS$0
M01 · FY2000 · RR
A LONGITUDINAL STUDY OF QUANTITATIVE CMV IN PYS W/ AIDS$0
M01 · FY2000 · RR
A LONGITUDINAL STUDY OF QUANTITATIVE CMV IN PYS W/ AIDS$0
M01 · FY2000 · RR
A LONGITUDINAL STUDY OF QUANTITATIVE CMV IN PYS W/ AIDS$0
M01 · FY2000 · RR
DDL/D4T/HU VS DDL/D4T/EFV VS PROTEASE INHIBITOR IN HIV PTS$0
M01 · FY2000 · RR
TRIAL OF SALVAGE ANTIRETROVIRAL THERAPIES FOR HIV PTS$0
M01 · FY2000 · RR
TRIAL OF SALVAGE ANTIRETROVIRAL THERAPIES FOR HIV PTS$0
M01 · FY2000 · RR
TRIAL OF SALVAGE ANTIRETROVIRAL THERAPIES FOR HIV PTS$0
M01 · FY2000 · RR
TRIAL OF SALVAGE ANTIRETROVIRAL THERAPIES FOR HIV PTS$0
M01 · FY2000 · RR
THE LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR
THE LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR
THE LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR